Name (Synonyms) | Correlation | |
---|---|---|
drug724 | NHANES smell and taste tests Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D000370 | Ageusia NIH | 1.00 |
D000857 | Olfaction Disorders NIH | 0.38 |
D014777 | Virus Diseases NIH | 0.14 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.06 |
D018352 | Coronavirus Infections NIH | 0.05 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0000224 | Decreased taste sensation HPO | 1.00 |
HP:0000458 | Anosmia HPO | 0.38 |
There is one clinical trial.
The overall objective of this project is to develop an emergent treatment protocol using adoptive T-cell therapy for the treatment of severe COVID-19. The central hypothesis is that SARS-CoV-2 specific T cells from convalescent donors who have recovered from COVID-19 can be manufactured expeditiously for the treatment of severe SARS-CoV-2 infections.
Description: Success of SARS-CoV-2 specific T cell manufacturing is defined as production of >200,000 T cells per donor. The success rate will be summarized descriptively.
Measure: Success rate in production of SARS-CoV-2 specific T cells from convalescent donor Time: Two weeks (The expected duration of donor participation is 2 weeks)